Meeting Banner
Abstract #4314

Detection of Early Response to Cyclophosphamide Treatment in a Myc-Driven Lymphoma Model Using Hyperpolarized 13C-Pyruvate and FDG-PET

Tiago B. Rodrigues1, 2, Mikko I. Kettunen, 23, David Y. Lewis1, Ferdia A. Gallagher1, 4, Eva Serrao1, 2, Dmitry Soloviev1, Kevin M. Brindle1

1Cambridge Research Institute, Cancer Research UK, Cambridge, United Kingdom; 2Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom; 3Cambridge Research Institute, Cancer Research UK,, Cambridge, United Kingdom; 4Departments of Radiology and Biochemistry, University of Cambridge, Cambridge, United Kingdom

Our main goal was to assess if hyperpolarized [1-13C]-pyruvate MRS could detect response within 24 hours of cyclophosphamide treatment in a Myc-driven lymphoma model and to compare it with FDG. Our results showed a 70% reduction in the pyruvate-lactate flux following treatment, whereas a more modest change was seen in FDG-PET. This demonstrates the feasibility of using hyperpolarized 13C-pyruvate to detect early treatment response in a transgenic mouse of lymphoma, being potentially a complement of FDG-PET as a clinical tool.